By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Companion diagnostics developer Biodesix today said that it has raised $7.1 million in a Series C round of financing, which will fund further development of its VeriStrat test.

The new round was led by existing investors, who provided $5.1 million in the round. The money will go toward ongoing commercialization of VeriStrat, a serum proteomic-based test to help guide treatment of patients with non-small cell lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.